In the last trading session, 1.07 million C4 Therapeutics Inc (NASDAQ:CCCC) shares changed hands as the company’s beta touched 2.95. With the company’s per share price at $1.51 changed hands at $0.08 or 5.59% during last session, the market valuation stood at $107.22M. CCCC’s last price was a discount, traded about -407.28% off its 52-week high of $7.66. The share price had its 52-week low at $1.09, which suggests the last value was 27.81% up since then. When we look at C4 Therapeutics Inc’s average trading volume, we note the 10-day average is 1.59 million shares, with the 3-month average coming to 1.21 million.
Analysts gave the C4 Therapeutics Inc (CCCC) stock a consensus recommendation rating of Hold, calculated at a mean rating of 1.86. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended CCCC as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. C4 Therapeutics Inc’s EPS for the current quarter is expected to be -0.38.
C4 Therapeutics Inc (NASDAQ:CCCC) trade information
Instantly CCCC was in green as seen at the end of in last trading. With action -3.21%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -67.32%, with the 5-day performance at -3.21% in the red. However, in the 30-day time frame, C4 Therapeutics Inc (NASDAQ:CCCC) is 20.80% up. Looking at the short shares, we see there were 6.38 million shares sold at short interest cover period of 6.29 days.
The consensus price target for the stock as assigned by Wall Street analysts is 13.5, meaning bulls need an upside of 88.81% from its current market value. According to analyst projections, CCCC’s forecast low is 10 with 20 as the target high. To hit the forecast high, the stock’s price needs a -1224.5% plunge from its current level, while the stock would need to soar -562.25% for it to hit the projected low.
C4 Therapeutics Inc (CCCC) estimates and forecasts
Year-over-year growth is forecast to reach -37.13% down from the last financial year.
Consensus estimates given by 5 financial analysts project the company’s revenue in the current quarter to hit an average of 5.24M. 5 analysts are of the opinion that C4 Therapeutics Inc’s revenue for the current quarter will be 5.44M. The company’s revenue for the corresponding quarters a year ago was 12.01M and 15.36M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -56.36%. The estimates for the next quarter sales put growth at -64.59%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -8.92%. The 2025 estimates are for C4 Therapeutics Inc earnings to decrease by -12.41%, but the outlook for the next 5-year period is at 6.31% per year.
CCCC Dividends
C4 Therapeutics Inc is expected to release its next quarterly earnings report on 2025-May-07.
C4 Therapeutics Inc (NASDAQ:CCCC)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 9.79% of C4 Therapeutics Inc shares while 91.87% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 101.83%. There are 91.87% institutions holding the C4 Therapeutics Inc stock share, with LYNX1 CAPITAL MANAGEMENT LP the top institutional holder. As of 2024-06-30, the company held 9.9993% of the shares, roughly 6.88 million CCCC shares worth $31.79 million.
RA CAPITAL MANAGEMENT, L.P. holds the second largest percentage of outstanding shares, with 7.0891% or 4.88 million shares worth $22.54 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were WASATCH FUNDS TRUST-Wasatch Ultra Growth Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . With 4.56 shares estimated at $6.88 million under it, the former controlled 6.42% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 2.92% of the shares, roughly 2.07 shares worth around $3.13 million.
